S
Sanjay Goel
Researcher at Albert Einstein College of Medicine
Publications - 241
Citations - 5667
Sanjay Goel is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 35, co-authored 187 publications receiving 4260 citations. Previous affiliations of Sanjay Goel include Yeshiva University & University College of Medical Sciences.
Papers
More filters
Journal ArticleDOI
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.
Vikas Mehta,Sanjay Goel,Rafi Kabarriti,Daniel Cole,Mendel Goldfinger,Ana Acuna-Villaorduna,Kith Pradhan,Raja Thota,Stan H. Reissman,Joseph A. Sparano,Benjamin A. Gartrell,Richard V. Smith,Nitin Ohri,Madhur Garg,Andrew D. Racine,Shalom Kalnicki,Roman Perez-Soler,Balazs Halmos,Amit Verma +18 more
TL;DR: Patients with cancer in a New York hospital system were much more vulnerable to COVID-19 death than the general population, with a case fatality rate that varied by cancer type and was 28% overall.
Journal ArticleDOI
PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab
Minaxi Jhawer,Sanjay Goel,Andrew J. Wilson,Cristina Montagna,Yi He Ling,Do Sun Byun,Shannon Nasser,Diego Arango,Joongho Shin,Lidija Klampfer,Leonard H. Augenlicht,Roman Perez Soler,John M. Mariadason +12 more
TL;DR: A priori screening of colon tumors for PTEN expression status and PIK3CA and Ras/BRAF mutation status could help stratify patients likely to benefit from this therapy.
Journal ArticleDOI
Novel patterns of response under immunotherapy.
Edith Borcoman,Yada Kanjanapan,Stéphane Champiat,Shumei Kato,Vincent Servois,Razelle Kurzrock,Sanjay Goel,Philippe L. Bedard,C. Le Tourneau,C. Le Tourneau +9 more
TL;DR: Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression, and the classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.
Journal ArticleDOI
Seroconversion rates following COVID-19 vaccination among patients with cancer.
Astha Thakkar,Jesus D. Gonzalez-Lugo,Niyati Goradia,Radhika Gali,Lauren C. Shapiro,Kith Pradhan,Shafia Rahman,So Yeon Kim,Brian Ko,R. Alejandro Sica,Noah Kornblum,Lizamarie Bachier-Rodriguez,Margaret E McCort,Sanjay Goel,Roman Perez-Soler,Stuart Packer,Joseph A. Sparano,Benjamin A. Gartrell,Della F. Makower,Y. Goldstein,Lucia Wolgast,Amit Verma,Balazs Halmos +22 more
TL;DR: In this paper, a validated antibody assay against SARS-CoV-2 spike protein was used to determine a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines.
Journal ArticleDOI
Patterns of Response and Progression to Immunotherapy
TL;DR: Classic RECIST remains a reasonable and rational method to assess response to immunotherapy, given the rarity of pseudoprogressions across tumor types and the recent description of hyperprogressions.